The PrKT03 trial of radiation + immunotherapy for localized prostate cancer

Back in September 2011, a company called Advantagene initiated a randomized, placebo-controlled, Phase III clinical trial (the PrKT01 trial) of an immunotherapeutic agent known as AdV-tk, together with with standard external beam radiation therapy, in highly-defined patients with newly diagnosed, localized prostate cancer. … READ MORE …

New Phase III trial of “gene suicide therapy” in localized prostate cancer

A biopharmaceutical company called Advantagene, Inc. announced last Thursday that it has reached agreement with the U.S. Food and Drug Administration regarding the conduct of a Phase III clinical trial of a vaccine-like treatment called ProstAtak™ — in combination with standard therapy — in the treatment of patients with newly diagnosed prostate cancer. … READ MORE …